Published in Arthritis Rheum on November 01, 1975
Amyloid protein SAA is associated with high density lipoprotein from human serum. Proc Natl Acad Sci U S A (1977) 3.04
Degradation of serum amyloid A protein by surface-associated enzymes of human blood monocytes. J Exp Med (1978) 2.09
Heterogeneity of human serum amyloid A proteins. J Exp Med (1980) 1.68
Mouse amyloid protein AA: Homology with nonimmunoglobulin protein of human and monkey amyloid substance. Proc Natl Acad Sci U S A (1976) 1.60
Kinetics of serum amyloid protein A in casein-induced murine amyloidosis. J Clin Invest (1977) 1.45
Partial amino acid sequence homology between an heredofamilial amyloid protein and human plasma prealbumin. J Clin Invest (1981) 1.41
Serum amyloid A: evidence for its origin in polymorphonuclear leukocytes. J Clin Invest (1978) 1.23
Suppression of in vitro antibody response by a serum factor (SAA) in experimentally induced amyloidosis. J Exp Med (1975) 1.21
Serum amyloid A (SAA) in viral infection: rubella, measles and subacute sclerosing panencephalitis (SSPE). Clin Exp Immunol (1982) 1.16
Levels of the serum amyloid A protein (SAA) in normal persons of different age groups. Clin Exp Immunol (1979) 0.99
Redistribution of amyloid deposits. Am J Pathol (1980) 0.92
Demonstration of protein AA in subcutaneous fat tissue obtained by fine needle biopsy. Ann Rheum Dis (1979) 0.85
Effects of amyloid induction on plasma protein turnover, and its implication. Am J Pathol (1976) 0.75
Suppression of in vitro antibody response of human peripheral blood lymphocytes by a heat-labile factor in normal human serum. Clin Exp Immunol (1981) 0.75
The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum (1982) 67.54
Whole genome sequencing of meticillin-resistant Staphylococcus aureus. Lancet (2001) 18.55
High throughput analysis of differential gene expression. J Cell Biochem Suppl (1998) 11.18
The systemic amyloidoses. N Engl J Med (1997) 7.32
A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science (1991) 4.09
Equating health status measures with item response theory: illustrations with functional status items. Med Care (2000) 3.98
Review: history of the amyloid fibril. J Struct Biol (2000) 3.49
Coronavirus mRNA synthesis involves fusion of non-contiguous sequences. EMBO J (1983) 3.13
Acute infectious arthritis. A review of patients with nongonococcal joint infections (with emphasis on therapy and prognosis). Am J Med (1976) 3.07
Amyloidosis. N Engl J Med (1967) 2.97
MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa1. J Biol Chem (2000) 2.83
The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM (1998) 2.81
Changing clinical spectrum of splenic abscess. A multicenter study and review of the literature. Am J Surg (1987) 2.63
Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases. Lancet (1993) 2.57
Models of acculturation and health behaviors among Latino immigrants to the US. Soc Sci Med (2001) 2.33
Autistic behavior, FMR1 protein, and developmental trajectories in young males with fragile X syndrome. J Autism Dev Disord (2001) 2.29
Role of the alpha2-integrin in osteoblast-specific gene expression and activation of the Osf2 transcription factor. J Biol Chem (1998) 2.26
Acute arthritis caused by gram-negative bacilli: a clinical characterization. Medicine (Baltimore) (1974) 2.25
Direct sequencing of the gene for Maryland/German familial amyloidotic polyneuropathy type II and genotyping by allele-specific enzymatic amplification. Genomics (1989) 2.17
High-resolution electron microscopic analysis of the amyloid fibril. J Cell Biol (1967) 2.16
Child health, developmental plasticity, and epigenetic programming. Endocr Rev (2010) 2.15
The pathogenesis and biochemistry of amyloidosis. J Pathol (1987) 2.15
Further characterization of amyloid-enhancing factor. Lab Invest (1982) 2.12
Binding of serum amyloid P-component (SAP) by amyloid fibrils. Clin Exp Immunol (1979) 2.08
Ultralight metallic microlattices. Science (2011) 2.05
Treatment of septic arthritis: comparison of needle aspiration and surgery as initial modes of joint drainage. Arthritis Rheum (1975) 2.03
Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab Dispos (2003) 1.98
Blockage of amyloid induction by colchicine in an animal model. J Exp Med (1974) 1.96
Role of granulocyte collagenase in collagen degradation. Am J Pathol (1972) 1.92
Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. Heart (1997) 1.90
Studies of immune deposits in synovial membranes and corresponding synovial fluids. J Lab Clin Med (1968) 1.90
Familial amyloidotic polyneuropathy. Trends Neurosci (1989) 1.89
Further mapping of markers around the centromere of human chromosome 19. Genomics (1987) 1.84
Synovial membrane histopathology in the differential diagnosis of rheumatoid arthritis, gout, pseudogout, systemic lupus erythematosus, infectious arthritis and degenerative joint disease. Medicine (Baltimore) (1978) 1.83
A clinical analysis of the course and prognosis of forty-two patients with amyloidosis. Am J Med (1968) 1.80
Progression from ischemic injury to infarct following middle cerebral artery occlusion in the rat. Am J Pathol (1993) 1.77
Sensitivity, specificity, and predictive value of abdominal fat aspiration for the diagnosis of amyloidosis. Arthritis Rheum (1989) 1.76
Intracellular ferritin accumulation in neural and extraneural tissue characterizes a neurodegenerative disease associated with a mutation in the ferritin light polypeptide gene. J Neuropathol Exp Neurol (2004) 1.76
High-resolution EEG: a new realistic geometry spline Laplacian estimation technique. Clin Neurophysiol (2001) 1.76
A mutation in apolipoprotein A-I in the Iowa type of familial amyloidotic polyneuropathy. Genomics (1990) 1.74
Primary structure of an amyloid prealbumin and its plasma precursor in a heredofamilial polyneuropathy of Swedish origin. Proc Natl Acad Sci U S A (1984) 1.74
Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation (2001) 1.73
Criteria for the classification of systemic lupus erythematosus--status 1972. Arthritis Rheum (1973) 1.71
Stabilization of Thylakoid Membranes by Spermine during Stress-induced Senescence of Barley Leaf Discs. Plant Physiol (1979) 1.70
Plasma protein constituents of amyloid fibrils. J Immunol (1967) 1.70
Autocrine induction of collagenase by serum amyloid A-like and beta 2-microglobulin-like proteins. Science (1989) 1.69
Amyloid enhancing factor-loaded macrophages in amyloid fibril formation. Lab Invest (1990) 1.69
The protofilament substructure of amyloid fibrils. J Mol Biol (2000) 1.69
C-reactive protein and the acute-phase response. J Lab Clin Med (1981) 1.67
Phenotypic variation in the response to the human immunodeficiency virus among derivatives of the CEM T and WIL-2 B cell lines. J Exp Med (1988) 1.67
Characterization of the amyloid fibril as a cross-beta protein. Proc Soc Exp Biol Med (1969) 1.66
Postmenopausal estrogen replacement therapy and the risk of developing systemic lupus erythematosus or discoid lupus. J Rheumatol (1998) 1.66
Inflammatory synovitis in degenerative joint disease. J Rheumatol (1982) 1.65
Genetic variants in the region harbouring IL2/IL21 associated with ulcerative colitis. Gut (2009) 1.65
Amyloidosis (concluded). N Engl J Med (1967) 1.64
Liver transplantation as a treatment for familial amyloidotic polyneuropathy. Ann Intern Med (1994) 1.63
Regional hippocampal alteration associated with cognitive deficit following experimental brain injury: a systems, network and cellular evaluation. Neuroscience (2005) 1.61
The constitution and genesis of amyloid. Int Rev Exp Pathol (1965) 1.61
Polymorphism of human plasma thyroxine binding prealbumin. Biochem Biophys Res Commun (1983) 1.60
Early development, temperament, and functional impairment in autism and fragile X syndrome. J Autism Dev Disord (2000) 1.60
Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia (2012) 1.60
From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients. Clin Pharmacol Ther (2015) 1.59
Nomenclature of amyloid fibril proteins. Report from the meeting of the International Nomenclature Committee on Amyloidosis, August 8-9, 1998. Part 1. Amyloid (1999) 1.59
Influx of leukocytes and platelets in an evolving brain infarct (Wistar rat). Am J Pathol (1994) 1.56
Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplant (2005) 1.55
Localized amyloidosis of the lower respiratory tract. Am Rev Respir Dis (1978) 1.54
Serum amyloid A protein in amyloidosis, rheumatic, and enoplastic diseases. Arthritis Rheum (1979) 1.53
The light and electron microscopic autoradiographic demonstration of local amyloid formation in spleen explants. Am J Pathol (1965) 1.52
Infrequent recovery of HIV from but robust exogenous infection of activated CD4(+) T cells in HIV elite controllers. Clin Infect Dis (2010) 1.50
Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med (1996) 1.49
Human serum amyloid A (SAA): biosynthesis and postsynthetic processing of preSAA and structural variants defined by complementary DNA. Biochemistry (1985) 1.49
Sensitivity and specificity of the echocardiographic features of cardiac amyloidosis. Am J Cardiol (1987) 1.49
Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood (1998) 1.48
The clinical features of elderly-onset rheumatoid arthritis. A comparison with younger-onset disease of similar duration. Arthritis Rheum (1985) 1.46
Kinetics of serum amyloid protein A in casein-induced murine amyloidosis. J Clin Invest (1977) 1.45
Lack of association of a restriction fragment length polymorphism for serum amyloid P gene with reactive amyloidosis. Arthritis Rheum (1989) 1.45
Synthesis and secretion of serum amyloid protein A (SAA) by hepatocytes in mice treated with casein. J Immunol (1980) 1.44
Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. Blood (1996) 1.42
Mobilized CD34+ cells selected as autografts in patients with primary light-chain amyloidosis: rationale and application. Transfusion (1998) 1.42
The x-ray crystal structure refinements of normal human transthyretin and the amyloidogenic Val-30-->Met variant to 1.7-A resolution. J Biol Chem (1993) 1.42
Partial amino acid sequence homology between an heredofamilial amyloid protein and human plasma prealbumin. J Clin Invest (1981) 1.41
Amyloidosis of the shoulder in patients on chronic hemodialysis: sonographic findings. AJR Am J Roentgenol (1996) 1.41
The tissue-specific nuclear matrix protein, NMP-2, is a member of the AML/CBF/PEBP2/runt domain transcription factor family: interactions with the osteocalcin gene promoter. Biochemistry (1995) 1.40
P-component (pentagonal unit) of amyloid: isolation, characterization, and sequence analysis. J Lab Clin Med (1974) 1.40
Isolation and identification by sequence analysis of experimentally induced guinea pig amyloid fibrils. J Exp Med (1974) 1.39
Biochemical and molecular genetic characterization of a new variant prealbumin associated with hereditary amyloidosis. J Clin Invest (1986) 1.38
Hereditary amyloidosis. Arthritis Rheum (1971) 1.38
The presence of gamma-carboxyglutamic acid in the proteins associated with ectopic calcification. Biochem Biophys Res Commun (1976) 1.38
Acute-phase proteins or tumour markers: the role of SAA, SAP, CRP and CEA as indicators of metastasis in a broad spectrum of neoplastic diseases. Scand J Immunol (1984) 1.38